Bayer’s KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes
New grade A recommendation in updated ADA Standards of Medical Care in Diabetes—2022 for KERENDIA® (finerenone) for improving cardiovascular (CV) outcomes and reducing risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D)1 Update is based on evidence from more than 13,000 patients in largest cardiorenal outcomes Phase … [Read more…]
